🇺🇸 FDA
Pipeline program

Diagnóstico prick control positivo, Diagnóstico prick Olea Europae, Diagnóstico prick control negativo, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae

API-EAO-2025-01

Phase 2 small_molecule active

Quick answer

Diagnóstico prick control positivo, Diagnóstico prick Olea Europae, Diagnóstico prick control negativo, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae, Diagnóstico prick Olea Europae for Allergies is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Allergies
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials